
Daily Smokers Have a More than 3 Times Increased Risk for MPN
Investigators in Denmark found that both current and ex-smokers have an increased risk of developing myeloproliferative neoplasms.
The results of a new study conducted by investigators in Denmark suggest that smoking may be a risk factor for the development of myeloproliferative neoplasms (MPN), a rare group of blood cancers.
The types of myeloproliferative disorders include chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia. The cause of these illnesses remains unknown, though the development of MPNs may be due to environmental and genetic factors, such as
Studies have also identified an association between
Using data from The Danish Health Examination Survey, a population-based study, the research team looked at the responses from 75,896 Danish citizens from 2 internet‐based questionnaires collected between September 2007 and October 2008. This included a basic questionnaire with questions on sociodemographic and health behavior, such as smoking status, self‐reported health, and living conditions, as well as a supplementary questionnaire concerning diet.
Based on the responses, the investigators categorized participants as individuals who never smoked (never-smokers), occasional or ex-smokers, or daily smokers. During the follow-up period, 70 survey respondents developed MPNs, including 41 women and 29 men with a median age of 63. The overall MPN case count included 23 cases of essential thrombocythemia, 17 cases of polycythemia vera, 10 cases of myelofibrosis, and 27 cases of unclassifiable MPN.
Of these MPN cases in study participants, 20 occurred in never-smokers, 35 in occasional or ex-smokers, and 15 in daily smokers. The study team determined that daily smokers had a 2.5 times higher risk of developing MPN than never smokers, and occasional and ex-smokers had a 1.9 times higher risk. Smokers who consumed more than 15 grams per day were 3.4 times more likely to develop any MPN, while those who consumed 15 grams or less were 2.1 times more likely.
In an interview with Rare Disease Report®, first author Kasper M. Pedersen, MD, explained that prior studies on the relationship between smoking and MPN have been carried out in small-scale, case-control studies and large prospective women’s cohorts. “In contrast, we followed a large sample of both women and men from the Danish general population and to this date, with 75,896 individuals, it is the largest cohort study specifically aimed at investigating smoking and the risk of Philadelphia-negative MPN,” Dr. Pedersen said.
“Another difference is that we only included cases of Philadelphia-negative MPN, whereas some, not all, of the prior studies have used different definitions of MPN as they either omitted some Philadelphia-negative MPNs or included other myeloproliferative disorders in their analyses—eg, myelodysplastic disorder and chronic myelogenous leukemia.”
Dr. Pedersen added that the research team hopes to further study the causal pathway between smoking and MPN.
“The association between smoking and MPN certainly deserves further investigation,” he said. “In this context, it is important to keep in mind that these traditional epidemiological studies cannot determine causality and that they are prone to certain limitations, such as residual confounding and reverse causality. We plan to carry out further large-scale studies examining the possible detrimental role of smoking in the development of MPN.”
























































































